Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153225 | 0.84 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL23126264 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL20153227 | 0.82 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL22811911 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL20070478 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL20149644 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL18390929 | 0.78 | RET (0.47) | CHRNB2CHRNA4RETTRPV6 | |
| SCHEMBL20153226 | 0.76 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3RET | |
| SCHEMBL20962681 | 0.76 | NNMT (0.46) | RET | |
| SCHEMBL22041916 | 0.75 | RET (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186959-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2276/4885CHRNA4 1977/4885CHRNB4 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.